Showing results (841-850 of 903) with videos related to

Sort By:
Pageof 91
Transfusion|October 21, 2025
In vitro and in vivo evaluation of leukoreduced red blood cells after automated separation of whole bloodRebecca L Sedjo, Gina K Aga, Elissa J Flaumenhaft, et al.
Clinical and Translational Radiation Oncology|March 7, 2024
Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastasesGamze Ugurluer, Famke L Schneiders, Stefanie Corradini, et al.
Journal of the American Society of Nephrology : JASN|May 7, 2016
Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic InflammationKirstin Andersen, Marie Sophie Kesper, Julian A Marschner, et al.
Heart (British Cardiac Society)|January 17, 2025
Determinants of medication adherence in patients with acute coronary syndrome: a secondary analysis of a randomised clinical trialRichard Kha, Haeri Min, Simone Marschner, et al.
Hemasphere|July 26, 2023
Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 PatientsHannes Treiber, Verena Nilius-Eliliwi, Nicole Seifert, et al.
Heart (British Cardiac Society)|August 8, 2023
Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressureEmily R Atkins, Alexander Chye, Thomas Lung, et al.
Clinical and Translational Radiation Oncology|June 8, 2026
Postoperative fractionated stereotactic radiotherapy for completely resected brain metastases with 25 Gy in five fractions: A single-center retrospective studySebastian H Maier, Alexander Nitschmann, Diana-Coralia Dehelean, et al.
Open Heart|April 9, 2026
Sex differences in risk factor control and medication adherence post-ACS: insights from the TEXTMEDS randomised clinical trialShiva Raj Mishra, Simone Marschner, Haeri Min, et al.
Molecular Oncology|December 19, 2020
Digital scoring of EpCAM and slug expression as prognostic markers in head and neck squamous cell carcinomasHenrik Schinke, Theresa Heider, Timm Herkommer, et al.
Trials|May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantTom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Pageof 91